Prestige Consumer Healthcare (NYSE:PBH) Announces Earnings Results, Misses Expectations By $0.02 EPS

Prestige Consumer Healthcare (NYSE:PBH) announced its quarterly earnings data on Thursday. The company reported $1.14 EPS for the quarter, missing the consensus estimate of $1.16 by ($0.02), FiscalAI reports. The business had revenue of $283.44 million for the quarter, compared to analyst estimates of $286.93 million. Prestige Consumer Healthcare had a net margin of 16.90% and a return on equity of 12.02%. The business’s revenue was down 2.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.22 earnings per share. Prestige Consumer Healthcare updated its FY 2026 guidance to 4.540-4.540 EPS.

Here are the key takeaways from Prestige Consumer Healthcare’s conference call:

• Clear Eyes supply is improving sequentially and management expects further progress in Q4 and through calendar 2026 after acquiring Pillar Five and installing a new high-speed line, which should enable internal production, SKU expansion and renewed marketing support.
• Q3 revenue of $283.4 million declined ~2.4% YoY (2.2% ex-FX) and adjusted EPS slipped to $1.14, driven primarily by Clear Eyes supply constraints and category softness in analgesics and cough & cold.
• Strong cash generation (YTD free cash flow of $208.8 million, +12.9%) underpins disciplined capital allocation: the company closed the ~$110 million Pillar Five deal and repurchased >$150 million of shares (~5% of outstanding), while maintaining net debt of ~$1 billion (leverage ~2.6x).
• Management narrowed fiscal 2026 guidance to about $1.1 billion in revenue and ~$4.54 adjusted EPS, expects Q4 adjusted gross margin ~57%, A&M just under 14% of sales and full-year G&A just over 10%, and will provide more 2027 detail on the May call.

Prestige Consumer Healthcare Price Performance

NYSE:PBH traded up $0.93 during trading hours on Friday, hitting $66.48. 422,278 shares of the stock were exchanged, compared to its average volume of 385,575. The firm’s fifty day moving average price is $63.19 and its 200 day moving average price is $64.06. Prestige Consumer Healthcare has a 52-week low of $57.25 and a 52-week high of $90.04. The company has a market cap of $3.20 billion, a P/E ratio of 17.59, a P/E/G ratio of 2.06 and a beta of 0.43. The company has a current ratio of 3.11, a quick ratio of 2.51 and a debt-to-equity ratio of 0.58.

Insider Activity at Prestige Consumer Healthcare

In related news, VP Jeffrey Zerillo sold 719 shares of the stock in a transaction on Friday, November 28th. The stock was sold at an average price of $60.00, for a total value of $43,140.00. Following the completion of the transaction, the vice president directly owned 42,329 shares of the company’s stock, valued at approximately $2,539,740. This represents a 1.67% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.40% of the company’s stock.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Large investors have recently modified their holdings of the business. Cerity Partners LLC lifted its stake in Prestige Consumer Healthcare by 5.9% in the 2nd quarter. Cerity Partners LLC now owns 3,884 shares of the company’s stock worth $310,000 after purchasing an additional 218 shares in the last quarter. Diversify Advisory Services LLC lifted its position in Prestige Consumer Healthcare by 4.6% during the third quarter. Diversify Advisory Services LLC now owns 5,837 shares of the company’s stock worth $354,000 after buying an additional 256 shares in the last quarter. Geneos Wealth Management Inc. raised its holdings in shares of Prestige Consumer Healthcare by 92.8% during the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock worth $48,000 after acquiring an additional 269 shares during the period. Martingale Asset Management L P grew its holdings in shares of Prestige Consumer Healthcare by 0.9% in the third quarter. Martingale Asset Management L P now owns 37,141 shares of the company’s stock valued at $2,318,000 after purchasing an additional 339 shares during the period. Finally, Quadrant Capital Group LLC raised its stake in Prestige Consumer Healthcare by 5.2% during the third quarter. Quadrant Capital Group LLC now owns 7,296 shares of the company’s stock worth $455,000 after purchasing an additional 360 shares during the period. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Wall Street Analysts Forecast Growth

PBH has been the topic of several recent research reports. Zacks Research upgraded Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research report on Monday, November 10th. Weiss Ratings reiterated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research note on Thursday, January 22nd. Oppenheimer dropped their price target on shares of Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 21st. Jefferies Financial Group cut their price objective on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a report on Friday, January 30th. Finally, Canaccord Genuity Group lowered their target price on shares of Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating on the stock in a research note on Friday, November 7th. Three analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, Prestige Consumer Healthcare has an average rating of “Hold” and a consensus target price of $80.60.

Key Stories Impacting Prestige Consumer Healthcare

Here are the key news stories impacting Prestige Consumer Healthcare this week:

• Positive Sentiment: Management highlighted progress restoring Clear Eyes supply and said availability is improving, which supports a rebound in that brand’s sales going forward. Prestige Consumer Healthcare narrows fiscal 2026 revenue outlook to $1.1B while advancing Clear Eyes supply recovery
• Positive Sentiment: The company narrowed and finalized its fiscal‑2026 revenue outlook to about $1.1 billion, which reduces uncertainty around full‑year expectations and may reassure investors. Prestige Consumer Healthcare Q3 revenue tops estimates, narrows guidance
• Neutral Sentiment: Management posted the full slide deck and call transcript; these provide detail on segment trends, margins and working‑capital dynamics for investors doing deeper diligence. Q3 2026 Earnings Call Transcript
• Negative Sentiment: Q3 results showed a small EPS miss: $1.14 reported vs. ~$1.16 consensus, and revenue of ~$283.4M was down roughly 2.4% year‑over‑year—factors that are short‑term headwinds for the stock. Prestige Consumer Healthcare (PBH) Q3 Earnings Lag Estimates
• Negative Sentiment: Fiscal‑2026 EPS guidance was set at 4.54 (company’s figure), essentially flat-to-slightly below some sell‑side consensus (~4.55), leaving limited upside in near‑term estimates. Press release: Third Quarter and Year-to-Date Fiscal 2026 Results

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).